The Clinical Implications of Aldosterone Escape in Congestive Heart Failure
- 1 August 2004
- journal article
- review article
- Published by Oxford University Press (OUP) in European Journal of Heart Failure
- Vol. 6 (5) , 539-545
Abstract
Angiotensin converting enzyme (ACE) inhibitor therapy does not reliably suppress aldosterone production, and ‘aldosterone escape’ occurs in up to 40% of patients with congestive heart failure (CHF). Aldosterone levels correlate with the risk of cardiovascular events. Aldosterone adversely affects the risk of cardiovascular events via mineralocorticoid receptors in the heart, blood vessels and other sites. Notably, aldosterone contributes to endothelial dysfunction and attenuates endothelium-dependent vasodilatation, at least partly by reducing nitric oxide bioavailability. Aldosterone also promotes myocardial fibrosis and cardiac remodelling by enhancing collagen synthesis, resulting in increased myocardial stiffness and increased left ventricular mass. These mechanisms mediated by aldosterone contribute to increased risk of ventricular arrhythmias and sudden cardiac death. Two major prospective trials, including one in which patients routinely received ACE inhibitor and beta blocker therapy, have shown that the use of an aldosterone blocker significantly reduces all-cause mortality, sudden cardiovascular death and hospitalisation in patients with acute or chronic left ventricular dysfunction or CHF. Inhibition of aldosterone's effect on mineralocorticoid receptors should now be considered standard therapy in these patient populations.Keywords
This publication has 40 references indexed in Scilit:
- Excess ldosterone Is Associated With Alterations of Myocardial Texture in Primary AldosteronismHypertension, 2002
- Clinical implications of increased plasma angiotensin II despite ACE inhibitor therapy in patients with congestive heart failureEuropean Heart Journal, 2000
- The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart FailureNew England Journal of Medicine, 1999
- Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery diseaseThe American Journal of Cardiology, 1995
- Aldosterone inhibits nitric oxide synthesis in rat vascular smooth muscle cells induced by interleukin-1 βEuropean Journal of Pharmacology: Molecular Pharmacology, 1995
- Chronic administration of aldosterone depresses baroreceptor reflex function in the dog.Hypertension, 1994
- The associations of levels of serum potassium and magnesium with ventricular premature complexes (the Framingham Heart Study)The American Journal of Cardiology, 1994
- Aldosterone reduces baroreceptor discharge in the dog.Hypertension, 1992
- Effects of Enalapril on Mortality in Severe Congestive Heart FailureNew England Journal of Medicine, 1987
- Captopril in heart failure. A double blind controlled trial.Heart, 1984